Non-Hodgkin Lymphoma Clinical Trials

• The patient (or their legally authorized representative) has voluntarily agreed to participate in this clinical trial and has signed the Informed Consent Form (ICF), indicating full understanding of the study's objectives and procedures.

• Aged 18 to 75 years, regardless of gender.

• Histologically or cytologically confirmed B-cell Non-Hodgkin Lymphoma (NHL) according to the WHO 2017 classification, including the following subtypes:

‣ Diffuse Large B-Cell Lymphoma (DLBCL): Including DLBCL, not otherwise specified (DLBCL, NOS); DLBCL associated with chronic inflammation; Primary Cutaneous DLBCL, leg type; and EBV-positive DLBCL, NOS.

⁃ High-Grade B-Cell Lymphoma (HGBL): Including HGBL, NOS; and HGBL with MYC and BCL2 and/or BCL6 rearrangements.

⁃ Primary Mediastinal Large B-Cell Lymphoma.

⁃ T-cell/Histiocyte-rich Large B-Cell Lymphoma.

⁃ Transformed DLBCL: DLBCL transformed from prior lymphomas (e.g., Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Marginal Zone Lymphoma).

⁃ Follicular Lymphoma Grade 3b (FL3b).

⁃ Mantle Cell Lymphoma.

• Patients must have received adequate prior therapy including an anti-CD20 monoclonal antibody and an anthracycline, unless contraindicated or intolerant (i.e., CD20-negative status, intolerance to anti-CD20 mAb, or contraindication to anthracyclines). Patients must meet the definition of Relapsed or Refractory (R/R) disease:

‣ Relapsed: Disease progression or recurrence after achieving a Complete Response (CR) to standard therapy.

⁃ Refractory: Best response of Stable Disease (SD) after at least 4 cycles of first-line therapy or at least 2 cycles of last-line therapy (≥2nd line), with SD duration ≤6 months after the last dose; or best response of Progressive Disease (PD) to the last treatment.

⁃ No response, disease progression, or relapse after Autologous Stem Cell Transplantation (ASCT).

⁃ Patients with transformed lymphoma who received chemotherapy prior to transformation and subsequently failed to achieve response, progressed, or relapsed after salvage therapy post-transformation.

• CD19 positivity confirmed by immunohistochemistry (IHC) or flow cytometry.

• ECOG performance status of 0 or 1.

• Estimated life expectancy of ≥12 weeks.

• At least one measurable lesion per the 2014 Lugano Criteria:

‣ For nodal lesions: Longest diameter \>1.5 cm.

⁃ For extranodal lesions: Longest diameter \>1.0 cm.

• Adequate major organ function defined as:

‣ Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥40% by echocardiogram.

⁃ Renal function: Serum creatinine ≤2.0 × ULN or Creatinine Clearance ≥50 mL/min (calculated by Cockcroft-Gault formula).

⁃ Hepatic enzymes: ALT and AST ≤3.0 × ULN (or ≤5.0 × ULN for subjects with hepatic involvement).

⁃ Bilirubin: Total bilirubin ≤2.0 × ULN (or ≤3.0 × ULN for subjects with Gilbert's syndrome).

⁃ Oxygenation: Oxygen saturation (SpO2) ≥ 92% while breathing room air.

⁃ Hematology: Neutrophil Count ≥ 1.0 × 10\^9/L; Platelet count ≥ 75 × 10\^9/L; Hemoglobin ≥ 80 g/L. (For subjects with bone marrow involvement: Neutrophil ≥ 0.5 × 10\^9/L and Platelet count ≥ 50 × 10\^9/L.)

• Women of childbearing potential must have a negative pregnancy test. All subjects must agree to use a highly effective method of contraception from the time of signing the ICF until 1 year after the infusion of the investigational product.